XETRA - Delayed Quote EUR

Novo Nordisk A/S (NOV.DE)

84.60

-0.26

(-0.31%)

At close: January 10 at 5:35:38 PM GMT+1

4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025

These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor.

Motley Fool 13 hours ago

MSFT

JNJ

V
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal

FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.

Zacks 14 hours ago

PFE

NVO
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Zacks yesterday

NVO

LLY
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month.

Investopedia yesterday

LLY

NVO
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy

Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.

Zacks yesterday

NVO

LLY
LLY Falls Around 14% in 3 Months: How to Play the Stock

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.

Zacks yesterday

LLY

NVO
5 questions facing pharma in 2025

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

BioPharma Dive yesterday

LLY

NVO
Novo Nordisk and Valo expand cardiometabolic drug partnership

The collaboration includes 20 drug programmes and could yield up to $4.6bn in milestone payments for Valo.

Pharmaceutical Technology yesterday

NVO
Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey

Companies have slowly been increasing coverage of GLP-1s for weight loss. Still, fewer than 50% do so.

Yahoo Finance 2 days ago

LLY

NONOF

NVO
Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition

Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products

GuruFocus.com 2 days ago

NVO

LLY
Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock "overdone."

Investopedia 2 days ago

NVO
Trump suggests Denmark tariff. How it could hit Novo Nordisk.

President-elect Donald Trump threatened higher tariffs against longtime ally Denmark over its ownership of Greenland as a Danish territory; Trump even floated the idea of the US purchasing Greenland. Denmark-based pharmaceutical company Novo Nordisk (NVO) is a major company that could be heavily impacted if Trump were to impose such tariffs. Yahoo Finance senior health reporter Anjalee Khemlani explains Novo Nordisk's presence in the US, especially as a GLP-1 weight-loss drug manufacturer, and what US companies like Eli Lilly (LLY) could have to gain if tariffs were levied against Denmark producers. Trump has proposed new tariff policy proposals that he could enact using the International Economic Emergency Powers Act (IEEPA). To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 2 days ago

LLY

NONOF

NVO
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs

Last month Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans to soon introduce a successor to Wegovy, its popular weight-loss drug. Novo is trying to develop a weight-loss treatment more powerful than Eli Lilly's rival Zepbound. Both Novo and Lilly are also testing their blockbuster obesity drugs for a range of conditions as they race to show that they have other health benefits.

Reuters 2 days ago

NVO
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due to their successful diabetes and weight loss medications. One study suggests that it may even help reduce the risk of developing Alzheimer's. There are many illnesses and conditions which are associated with being obese, which is why it's paramount for many patients to maintain a healthy weight.

Motley Fool 2 days ago

NVO

LLY
5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of America addresses the company’s earnings and more.

Barrons.com 2 days ago

NVO

LLY
Does Novo Nordisk A/S (NVO) Have an Attractive Valuation?

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. During a time of momentum-driven returns and heightened investor optimism following Donald Trump’s re-election, the more defensively oriented Strategy lagged behind. The S&P 500 Index advanced 2.41% in […]

Insider Monkey 2 days ago

NVO
The market’s wobbling. Here are BlackRock’s shields for the biggest risks.

Here are the hedges the $11 trillion asset manager recommends for the concerns weighing on investor minds.

MarketWatch 2 days ago

BLK

NVO
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular diseaseExpanded collaboration includes near-term payments totalling up to 190 million US dollars, while Valo is eligible to receive milestone payments of approximately 4.6 billion dollars, plus R&D funding and potential royalty payments Bagsværd, Denmark and Lexington, Massachusetts, US, 8 January 2025

GlobeNewswire 2 days ago

NONOF

NVO
3 trial readouts that could shake up the obesity market this year

A wave of new weight loss treatments is on the way, and drugmakers are scrambling for a foot in the door.

Pharma Voice 2 days ago

NVO

LLY
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.

Zacks 3 days ago

NVO

Performance Overview

Return	NOV.DE	OMX Copenhagen 25 Index
YTD	-0.20%	+1.64%
1-Year	-5.28%	-2.78%
3-Year	+153.01%	-3.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NOV.DE)

4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025

Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal

Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?

Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea

NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy

LLY Falls Around 14% in 3 Months: How to Play the Stock

5 questions facing pharma in 2025

Novo Nordisk and Valo expand cardiometabolic drug partnership

Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey

Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition

Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'

Trump suggests Denmark tariff. How it could hit Novo Nordisk.

Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs

This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly

5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher

Does Novo Nordisk A/S (NVO) Have an Attractive Valuation?

The market’s wobbling. Here are BlackRock’s shields for the biggest risks.

Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

3 trial readouts that could shake up the obesity market this year

Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights

Performance Overview